BRC Announces Development and Regulatory Milestone Following Successful Type C CMC Meeting with FDA, Advancing Clinical Development of Multiple Therapeutic Candidates
Biopharmaceutical Research Company Announces First Dose of BRC-002, a First-in-Class Cannabinoid Therapeutic for Complex Regional Pain Syndrome (CRPS), in Investigator-Initiated Study